Why the study?
What is the appropriate antithrombotic therapy and perioperative management for stroke prevention in patients with non-valvular atrial fibrillation?
What is the appropriate antithrombotic therapy and perioperative management for stroke prevention in patients with non-valvular atrial fibrillation?
This review outlines the Japanese evidence-based approach to stroke prevention in NVAF, emphasizing age-adjusted INR targets for warfarin and the ineffectiveness of antiplatelet therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Masahiro Yasaka (2008) conducted a review in Non-valvular atrial fibrillation (NVAF). Antithrombotic therapy (Warfarin) was evaluated on Stroke prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: